Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.310
0.00 (0.00%)
At close: Dec 5, 2025, 4:00 PM EST
1.330
+0.020 (1.53%)
After-hours: Dec 5, 2025, 7:47 PM EST
Heron Therapeutics Revenue
Heron Therapeutics had revenue of $38.21M in the quarter ending September 30, 2025, with 16.47% growth. This brings the company's revenue in the last twelve months to $155.10M, up 12.60% year-over-year. In the year 2024, Heron Therapeutics had annual revenue of $144.29M with 13.57% growth.
Revenue (ttm)
$155.10M
Revenue Growth
+12.60%
P/S Ratio
1.33
Revenue / Employee
$1,271,287
Employees
122
Market Cap
240.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 144.29M | 17.24M | 13.57% |
| Dec 31, 2023 | 127.04M | 19.37M | 17.99% |
| Dec 31, 2022 | 107.67M | 21.33M | 24.70% |
| Dec 31, 2021 | 86.35M | -2.29M | -2.59% |
| Dec 31, 2020 | 88.64M | -57.33M | -39.28% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
HRTX News
- 1 day ago - Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) - GlobeNewsWire
- 4 weeks ago - Heron Therapeutics, Inc. (HRTX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress - GlobeNewsWire
- 5 weeks ago - Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors - GlobeNewsWire
- 6 weeks ago - Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - GlobeNewsWire
- 4 months ago - Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value - PRNewsWire
- 4 months ago - Heron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Heron (HRTX) Q2 Acute Care Jumps 56% - The Motley Fool